Semaglutide · 3 min read
One receptor, four effects: glucose-dependent insulin, glucagon suppression, delayed gastric emptying, and central appetite signaling. The mechanism behind Ozempic, Wegovy, and the new pill.
One receptor, four effects: glucose-dependent insulin, glucagon suppression, delayed gastric emptying, and central appetite signaling. The mechanism behind Ozempic, Wegovy, and the new pill.
Semaglutide is a modified analog of human GLP-1 — 94% identical to the native hormone, engineered with an amino-acid substitution and a fatty-diacid chain that binds albumin, stretching a two-minute natural signal into a drug with a roughly one-week half-life. That one change in duration, applied to one receptor, produces everything Ozempic, Wegovy, Rybelsus, and the 2026 Wegovy tablet do.
Activating the GLP-1 receptor does four clinically relevant things. In the pancreas, it amplifies insulin secretion only when glucose is elevated — the glucose-dependence that makes solo hypoglycemia rare — while suppressing inappropriate glucagon. In the stomach, it slows gastric emptying, extending post-meal fullness (and explaining both the satiety and the nausea). In the brain, it acts on hypothalamic and hindbrain circuits to reduce hunger, quiet food-reward signaling, and — in many patients' words — turn down the "food noise." And across metabolism, the resulting intake reduction drives the weight loss, with downstream improvements in blood pressure, lipids, liver fat, and inflammation that largely track the weight.
Semaglutide's obesity dose (2.4 mg weekly) is higher than its original diabetes doses because appetite circuits need more receptor activation than glycemic ones. This is why dose-capped programs matter to price comparisons: a compounded plan limited to 0.6 mg is pharmacologically a different offer than the STEP-trial regimen, whatever the price tag says. The titration ladder — 0.25 to 2.4 mg over about sixteen weeks — exists to outpace the nausea, not the physiology; details in the dosing guide.
Semaglutide is the class member with outcome trials attached: SELECT showed a 20% reduction in major cardiovascular events in people with cardiovascular disease and overweight without diabetes, and subsequent work added kidney (FLOW) and other endpoints — the reason Wegovy holds indications no competitor yet matches, covered in the STEP and SELECT explainer. Mechanistically it remains a pure GLP-1 story; tirzepatide's added GIP agonism is what buys its larger average weight loss, a comparison drawn fully in tirzepatide vs. semaglutide.
Primarily by reducing intake: central appetite suppression and reduced food reward, reinforced by slowed gastric emptying — with glucose-dependent insulin effects handling the glycemic side.
Appetite effects begin within the first weeks, but the full 2.4 mg dose isn't reached until about week 17 of standard titration, and trial-level average loss (14.9% in STEP 1) accrued over 68 weeks.
Its insulin effect is glucose-dependent — the receptor amplifies insulin secretion only when glucose is elevated — so solo hypoglycemia is uncommon; risk rises mainly when combined with insulin or sulfonylureas.